<DOC>
	<DOCNO>NCT00773279</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial ass compare effect blood sugar control insulin detemir insulin aspart insulin detemir alone administer insulin pen PDS290 ( FlexTouch® ) versus Novo Nordisk market insulin pen ( FlexPen® ) subject type 1 type 2 diabetes mellitus . Furthermore , subject 's preference device investigate use questionnaire .</brief_summary>
	<brief_title>Efficacy , Safety Preference Study Insulin Pen PDS290 vs. Novo Nordisk Marketed Insulin Pen Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Informed consent obtain trialrelated activity Subjects diagnose type 1 type 2 diabetes . If type 2 diabetic , treatment without oral anti diabetic medication allow Current user vial/syringe ( pen naïve ) treat shortacting insulin ( insulin aspart , glulisine lispro ) daily longacting insulin ( detemir glargine ) daily longacting insulin ( detemir glargine ) alone Treatment insulin ( i.e . aspart , glulisine , lispro , detemir glargine ) least 6 month Body Mass Index ( BMI ) less 45.0 kg/m^2 HbA1c le equal 9.0 % screen visit base analysis central laboratory Able willing adhere trialspecific insulin regimen entire trial period Females childbearing potential pregnant , breastfeed intend become pregnant inadequate contraceptive technique trial period ( adequate contraceptive measure consider intrauterine device , oral contraceptive barrier method ) Previous participation trial ( screen visit ) Systemic drug may influence glycaemic control ( e.g. , corticosteroid ) Known suspect allergy trial product ( ) relate product Known suspected abuse alcohol drug abuse Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Previous treatment sitagliptin Clinically significant , active ( past 12 month ) disease gastrointestinal , neurological , genitourinary , haematological system Cardiac disease define : Decompensated heart failure ( New York Heart class III IV , unstable angina pectoris within past 6 month study enrolment , myocardial infarction within past 12 month clinically significant history arrhythmias conduction delay electrocardiogram ( ECG ) past 12 month Any severe acute chronic illness judge Investigator Recurrent major hypoglycaemia ( define severe central nervous system dysfunction associate hypoglycaemia , require assistance another person ) hypoglycaemia unawareness ( defined condition subject longer experience usual warning sign hypoglycaemia ; symptom hypoglycaemia may different , less pronounce even absent ) hospitalisation diabetic ketoacidosis previous six month Any condition Investigator judge would interfere trial participation evaluation result ( i.e . plan diagnostic therapeutic medical intervention surgery ) Participated another clinical trial receive investigational drug within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>